Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

icrucumab

A fully human IgG1 monoclonal antibody directed against human vascular endothelial growth factor receptor 1 (VEGFR-1/FLT-1) with potential antiangiogenesis and antineoplastic activities. Icrucumab specifically binds to and inhibits the activity of VEGFR-1, which may prevent the activation of downstream signaling pathways and so inhibit tumor angiogenesis; the subsequent reduction in tumor nutrient supply may inhibit tumor cell proliferation. Tumor cell overexpression of VEGFR-1 may be associated with tumor angiogenesis and tumor cell proliferation and invasion; VEGFR-1 may modulate VEGFR-2 signaling.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-vascular endothelial growth factor receptor-1 monoclonal antibody IMC-18F1
anti-VEGFR-1 monoclonal antibody IMC-18F1
Code name:IMC-18F1
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search